|
1
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fry AM: The Nek2 protein kinase: A novel
regulator of centrosome structure. Oncogene. 21:6184–6194. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fletcher L, Cerniglia GJ, Nigg EA, Yend TJ
and Muschel RJ: Inhibition of centrosome separation after DNA
damage: A role for Nek2. Radiat Res. 162:128–135. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hayward DG, Clarke RB, Faragher AJ, Pillai
MR, Hagan IM and Fry AM: The centrosomal kinase Nek2 displays
elevated levels of protein expression in human breast cancer.
Cancer Res. 64:7370–7376. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsunoda N, Kokuryo T, Oda K, Senga T,
Yokoyama Y, Nagino M, Nimura Y and Hamaguchi M: Nek2 as a novel
molecular target for the treatment of breast carcinoma. Cancer Sci.
100:111–116. 2009. View Article : Google Scholar
|
|
6
|
Cappello P, Blaser H, Gorrini C, Lin DC,
Elia AJ, Wakeham A, Haider S, Boutros PC, Mason JM, Miller NA, et
al: Role of Nek2 on centrosome duplication and aneuploidy in breast
cancer cells. Oncogene. 33:2375–2384. 2014. View Article : Google Scholar
|
|
7
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Upregulation of NEK2 is associated with drug resistance in
ovarian cancer. Oncol Rep. 31:745–754. 2014.
|
|
8
|
Zhong X, Guan X, Dong Q, Yang S, Liu W and
Zhang L: Examining Nek2 as a better proliferation marker in
non-small cell lung cancer prognosis. Tumour Biol. 35:7155–7162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou W, Yang Y, Xia J, Wang H, Salama ME,
Xiong W, Xu H, Shetty S, Chen T, Zeng Z, et al: NEK2 induces drug
resistance mainly through activation of efflux drug pumps and is
associated with poor prognosis in myeloma and other cancers. Cancer
Cell. 23:48–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Drozdov I, Bornschein J, Wex T, Valeyev
NV, Tsoka S and Malfertheiner P: Functional and topological
properties in hepatocellular carcinoma transcriptome. PLoS One.
7:e355102012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Min J, Li X, Huang K, Tang H, Ding X, Qi
C, Qin X and Xu Z: Phloretin induces apoptosis of non-small cell
lung carcinoma A549 cells via JNK1/2 and p38 MAPK pathways. Oncol
Rep. 34:2871–2879. 2015.PubMed/NCBI
|
|
12
|
Deng L, Ren Z, Jia Q, Wu W, Shen H and
Wang Y: Schedule- dependent antitumor effects of 5-fluorouracil
combined with sorafenib in hepatocellular carcinoma. BMC Cancer.
13:3632013. View Article : Google Scholar
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neal CP, Fry AM, Moreman C, McGregor A,
Garcea G, Berry DP and Manson MM: Overexpression of the Nek2 kinase
in colorectal cancer correlates with beta-catenin relocalization
and shortened cancer-specific survival. J Surg Oncol. 110:828–838.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhong X, Guan X, Liu W and Zhang L:
Aberrant expression of NEK2 and its clinical significance in
non-small cell lung cancer. Oncol Lett. 8:1470–1476.
2014.PubMed/NCBI
|
|
17
|
Jinek M and Doudna JA: A three-dimensional
view of the molecular machinery of RNA interference. Nature.
457:405–412. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moazed D: Small RNAs in transcriptional
gene silencing and genome defence. Nature. 457:413–420. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siomi H and Siomi MC: On the road to
reading the RNA-interference code. Nature. 457:396–404. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Helps NR, Luo X, Barker HM and Cohen PT:
NIMA-related kinase 2 (Nek2), a cell-cycle-regulated protein kinase
localized to centrosomes, is complexed to protein phosphatase 1.
Biochem J. 349:509–518. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bahmanyar S, Kaplan DD, Deluca JG,
Giddings TH Jr, O'Toole ET, Winey M, Salmon ED, Casey PJ, Nelson WJ
and Barth AI: beta-Catenin is a Nek2 substrate involved in
centrosome separation. Genes Dev. 22:91–105. 2008. View Article : Google Scholar :
|
|
22
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Faragher AJ and Fry AM: Nek2A kinase
stimulates centrosome disjunction and is required for formation of
bipolar mitotic spindles. Mol Biol Cell. 14:2876–2889. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hayward DG and Fry AM: Nek2 kinase in
chromosome instability and cancer. Cancer Lett. 237:155–166. 2006.
View Article : Google Scholar
|
|
26
|
Xiao L, Gong LL, Yuan D, Deng M, Zeng XM,
Chen LL, Zhang L, Yan Q, Liu JP, Hu XH, et al: Protein
phosphatase-1 regulates Akt1 signal transduction pathway to control
gene expression, cell survival and differentiation. Cell Death
Differ. 17:1448–1462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dan HC, Cooper MJ, Cogswell PC, Duncan JA,
Ting JP and Baldwin AS: Akt-dependent regulation of NF-κB is
controlled by mTOR and Raptor in association with IKK. Genes Dev.
22:1490–1500. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fodde R and Tomlinson I: Nuclear
beta-catenin expression and Wnt signalling: In defence of the
dogma. J Pathol. 221:239–241. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gehrke I, Gandhirajan RK and Kreuzer KA:
Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and
haematological cancers: Multiplicity of therapeutic options. Eur J
Cancer. 45:2759–2767. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kops GJ, Weaver BA and Cleveland DW: On
the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev
Cancer. 5:773–785. 2005. View
Article : Google Scholar : PubMed/NCBI
|
